Kurma Partners

Sunrise focuses on addressing the widespread issue of sleep disorders, particularly sleep apnea, which affects nearly one billion people globally. The company has developed a 3-gram sensor that provides a rapid, at-home diagnosis of sleep apnea, utilizing trigeminal drive analysis to detect respiratory events. This certified medical device connects seamlessly to a smartphone, allowing for easy use and immediate results. Clinical studies have demonstrated that Sunrise's technology matches the accuracy of traditional in-lab sleep studies but at a significantly lower cost. After testing, patients can consult with certified sleep doctors online or visit local sleep centers, streamlining the diagnostic process. With a large percentage of sleep apnea cases remaining undiagnosed, Sunrise offers a crucial solution for patients, caregivers, and insurers, enhancing the accessibility and efficiency of sleep disorder diagnostics.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatment. Established in 2010, the company offers a range of products including the SteriSpine PS kit for spinal fractures and degenerative pathologies, the SteriSpine VA platform for Kyphoplasty and Cement systems, and instrumentation for lumbar and cervical cages, including Cedar, Elm, and Walnut models. Safe Orthopaedics aims to enhance surgical outcomes through its innovative solutions in spinal surgery, catering to both domestic and international markets.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatment. Established in 2010, the company offers a range of products including the SteriSpine PS kit for spinal fractures and degenerative pathologies, the SteriSpine VA platform for Kyphoplasty and Cement systems, and instrumentation for lumbar and cervical cages, including Cedar, Elm, and Walnut models. Safe Orthopaedics aims to enhance surgical outcomes through its innovative solutions in spinal surgery, catering to both domestic and international markets.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatment. Established in 2010, the company offers a range of products including the SteriSpine PS kit for spinal fractures and degenerative pathologies, the SteriSpine VA platform for Kyphoplasty and Cement systems, and instrumentation for lumbar and cervical cages, including Cedar, Elm, and Walnut models. Safe Orthopaedics aims to enhance surgical outcomes through its innovative solutions in spinal surgery, catering to both domestic and international markets.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatment. Established in 2010, the company offers a range of products including the SteriSpine PS kit for spinal fractures and degenerative pathologies, the SteriSpine VA platform for Kyphoplasty and Cement systems, and instrumentation for lumbar and cervical cages, including Cedar, Elm, and Walnut models. Safe Orthopaedics aims to enhance surgical outcomes through its innovative solutions in spinal surgery, catering to both domestic and international markets.